In 2012, we shipped our first smartwatch. Back then, the idea of a wrist-worn computer that could track your heart rate was still science fiction to most manufacturers. We spent the next 14 years learning everything there is to know about putting medical-grade sensors on human bodies—ECG chipsets, PPG calibration, FDA 510(k) submissions, manufacturing tolerances across 30+ countries.
In 2026, we’re making the biggest strategic bet in our company’s history: smart rings are the next medical wearable form factor, and we’re going all in.
The Decision That Took 18 Months
We didn’t wake up one morning and decide rings were cool. This was an 18-month internal debate. Our engineering team argued that rings have severe space constraints—no display, tiny battery, limited antenna real estate. Our sales team pointed out that watches already have a $35 billion market. Why risk it?
But the data kept stacking up. Three factors broke the tie:
- Sleep compliance. We surveyed 200+ end-users of our watch-based sleep tracking solutions. Roughly 40% said they don’t wear their watch to bed—it’s uncomfortable, they charge it at night, or they simply forget. Ring users? Over 90% nightly wear compliance in our internal beta. You can’t measure what people won’t wear.
- Clinical demand shift. In 2024, we received 12 RFQs for smart rings from hospitals and nursing homes. In 2025, that number jumped to 47. The institutions driving healthcare spending are voting with their procurement dollars.
- Sensor maturity. The PPG modules we spent a decade refining for wrist-based measurement? They actually perform better on the finger. The palmar digital artery gives cleaner signals than the radial artery, with less motion artifact. We didn’t have to start from zero—we just had to shrink what we already knew worked.
What 15 Years of Watch Manufacturing Taught Us (That Rings Can’t Skip)
This is the part most ring startups get wrong. They think a ring is a simpler device, so it’s easier to build. That’s exactly backwards.
1. ECG Is Not a Feature—It’s a Regulatory Gauntlet
We’ve been through four FDA 510(k) clearance cycles for ECG-enabled watches. Each one taught us something new about clinical validation protocols, lead placement equivalence, and the infinite patience required to deal with regulators across 30 countries. When we designed our first ECG ring, we didn’t start with the PCB layout—we started with the submission checklist. The algorithm team that built our watch ECG pipeline is the same team now optimizing for single-lead finger contact.
2. PPG Calibration Is a Supply Chain Problem
Getting consistent PPG readings across 10,000 units requires more than a good sensor. It requires controlling for LED wavelength tolerance, photodiode sensitivity variance, and optical path geometry—all at the component sourcing level. We’ve spent 14 years building supplier relationships where we can specify and enforce these tolerances. A ring startup buying off-the-shelf modules doesn’t have this leverage.
3. 12 Sizes, One Manufacturing Line
Watches have two or three band sizes. Rings have twelve. Each size requires its own injection mold, its own PCB layout variant, its own battery geometry. The logistics of forecasting demand across 12 SKUs, managing inventory, and keeping per-unit costs down is a problem our watch business never faced. We solved it by adapting our flexible production line approach—the same method we use to run 15+ watch models simultaneously—to ring manufacturing.
The Migration Strategy: Watch Trust → Ring Growth
We’re not abandoning watches. Our watch business is the foundation—28 years of electronics manufacturing, 14 years of wearable ODM, ISO 13485-certified facilities, and partnerships with hospitals and distributors across 30+ countries. That trust is the bridge.
Every ring we ship carries the same QA system that our ECG watches go through. The same production line management. The same regulatory team. The same component traceability. Our B2B clients don’t have to choose between “experienced watch manufacturer” and “innovative ring supplier”—they get both, from one factory, under one quality system.
The Numbers Behind the Decision
The global smart ring market was valued at approximately $210 million in 2024, projected to reach $1.4 billion by 2032 (Grand View Research, 2025). But the B2B segment—clinics, nursing homes, corporate wellness programs, clinical trial data collection—is growing faster than consumer retail. The CDC reports that 6 in 10 American adults have at least one chronic condition requiring ongoing monitoring. Rings are the most unobtrusive way to collect that data continuously.
Our watch business taught us how to build. Our ring business will teach us how to scale. And scale is where the real opportunity lies.
What This Means for Our B2B Partners
If you’re a hospital group, a nursing home chain, a telehealth platform, or a clinical research organization looking at smart rings, here’s what you should ask any potential supplier:
- Can you show me your ECG 510(k) clearance documentation?
- What’s your PPG calibration tolerance across production batches?
- How do you handle 12-size inventory forecasting?
- Do you have ISO 13485 certification for your entire production line?
- Can the same factory also supply watches for patients who prefer wrist-worn devices?
If they can’t answer all five, you’re talking to a lab, not a manufacturer.
We bet on rings because we spent 15 years learning what it takes to make medical wearables that actually work. Now we’re putting everything we learned into a device you can wear on your finger.
— Lin Jie, CEO, Geyan Technology Innovation
Book a 15-minute ring project consultation: jine@xdunmedical.com | xdunmedical.com